Planet 13 Holdings (PLNH) Non-Current Assets (2021 - 2026)
Planet 13 Holdings' (PLNH) quarterly Non-Current Assets came in at $109.1 million in Q1 2026, down 28.26% year-on-year from $152.1 million in Q1 2025, and down 1.85% on a QoQ basis from $111.1 million in Q4 2025.
Planet 13 Holdings (PLNH) Non-Current Assets (2021 - 2026) Analysis & Trends
Planet 13 Holdings (PLNH) has 6 years of Non-Current Assets data on file, last reported at $109.1 million in Q1 2026.
- On a quarterly basis, Non-Current Assets fell 28.26% year-over-year to $109.1 million in Q1 2026; TTM through Mar 2026 was $484.9 million, a 28.38% decrease from a year earlier, with the FY2025 full-year figure at $111.1 million, down 27.09% from the prior year.
- Non-Current Assets for Q1 2026 stood at $109.1 million, down from $111.1 million in the prior quarter.
- Over the last five years, Non-Current Assets for PLNH reached as high as $197.2 million in Q2 2022 and fell as low as $104.4 million in Q4 2023.
- Historically, Non-Current Assets has averaged $151.1 million across 5 years, with a median of $152.4 million in 2024.
- Across the five-year window, Non-Current Assets jumped 51.07% in 2024 and plunged 38.61% in 2025, its largest moves.
- Year by year, Non-Current Assets stood at $163.1 million in 2022, then tumbled by 35.98% to $104.4 million in 2023, then jumped by 45.96% to $152.4 million in 2024, then slipped by 27.09% to $111.1 million in 2025, then fell by 1.85% to $109.1 million in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $109.1 million in Q1 2026, $111.1 million in Q4 2025, and $113.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Planet 13 Holdings | 39.35 Mn | 23.09 Mn | 9.41 Mn | 109.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 109.08 Mn |
| Dec 31, 2025 | 111.14 Mn |
| Sep 30, 2025 | 113.43 Mn |
| Jun 30, 2025 | 151.21 Mn |
| Mar 31, 2025 | 152.06 Mn |
| Dec 31, 2024 | 152.44 Mn |
| Sep 30, 2024 | 184.78 Mn |
| Jun 30, 2024 | 187.76 Mn |
| Mar 31, 2024 | 104.64 Mn |
| Dec 31, 2023 | 104.44 Mn |
| Sep 30, 2023 | 122.31 Mn |
| Jun 30, 2023 | 163.36 Mn |
| Mar 31, 2023 | 166.01 Mn |
| Dec 31, 2022 | 163.13 Mn |
| Sep 30, 2022 | 194.78 Mn |
| Jun 30, 2022 | 197.15 Mn |
| Mar 31, 2022 | 191.02 Mn |
| Dec 31, 2021 | 135.80 Mn |